Osseous wound repair under inhibition of the axis of advanced glycation end-products and the advanced glycation end-products receptor
Journal
Journal of the Formosan Medical Association
Journal Volume
114
Journal Issue
10
Pages
973-980
Date Issued
2015
Author(s)
Abstract
Background/Purpose: Blockade of advanced glycation end-products (AGE) is able to reduce diabetic complications and control periodontitis. This study aimed to determine whether the application of aminoguanidine (AG), an AGE inhibitor, or N-phenacylthiazolium bromide (PTB), an AGE breaker, facilitates the healing of an osseous wound in non-diabetic animals. Methods: 2.6 mm diameter full-thickness osseous wounds were created bilaterally in 54 healthy Sprague-Dawley rats. Rats received daily normal saline, AG, or PTB injections respectively and were euthanized after 7 days, 14 days, or 28 days (n = 6). The wound healing pattern was assessed by micro-computed tomography, histology, histochemistry for the fiber arrangement, and the gene expression levels of AGE receptor, tumor necrosis factor-α, type I collagen, and fibronectin. Results: Under the AG and PTB administration, osteogenesis was apparently promoted in the early stages of healing, but the union of the osseous wound and the fibril re-arrangement was apparently retarded. No significant difference was found in any of the micro-computed tomography parameters as compared to the control in the first 14 days, whereas the relative bone volume was significantly higher in the control at Day 28. AGE receptor and tumor necrosis factor-α were depressed in the PTB group, but only temporarily at Day 14 in the AG group. Therefore, at Day 14, type I collagen was significantly upregulated in the PTB group, and fibronectin was significantly increased in the AG group. Conclusion: Anti-AGE agents reduced inflammation but did not apparently facilitate osteogenesis during the osseous wound repair. ? 2013.
SDGs
Other Subjects
advanced glycation end product; advanced glycation end product receptor; aminoguanidine; collagen type 1; fibronectin; n phenacylthiazolium bromide; protein inhibitor; sodium chloride; tumor necrosis factor alpha; unclassified drug; advanced glycation end product; advanced glycation end product receptor; Ager protein, rat; aminoguanidine; collagen type 1; fibronectin; guanidine derivative; N-phenacylthiazolium bromide; thiazole derivative; tumor necrosis factor; animal experiment; animal model; animal tissue; Article; bone development; bone injury; bone mass; collagen fiber; controlled study; drug effect; drug efficacy; drug mechanism; gene expression; histochemistry; histology; inflammation; male; micro-computed tomography; nonhuman; protein expression; quantitative analysis; rat; real time polymerase chain reaction; signal transduction; wound healing; animal; disease model; drug effects; Mandibular Injuries; metabolism; Sprague Dawley rat; wound healing; Advanced Glycosylation End Product-Specific Receptor; Animals; Collagen Type I; Disease Models, Animal; Fibronectins; Glycosylation End Products, Advanced; Guanidines; Male; Mandibular Injuries; Rats; Rats, Sprague-Dawley; Thiazoles; Tumor Necrosis Factor-alpha; Wound Healing; X-Ray Microtomography
Publisher
Elsevier
Type
journal article